We conclude that, despite compelling circumstantial evidence, it is unlikely that ACSBG1 directly contributes to the pathology of XALD, decreasing its potential as a therapeutic target. This evidence concerns the gene ACSBG1 and X-linked adrenoleukodystrophy.